Press Releases

Press Releases

Date Title & Summary Additional Formats
03/26/19
Cidara Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Six poster presentations include new analyses from Phase 2 STRIVE clinical trial of rezafungin Four oral presentations include first scientific presentation of new data highlighting the potential of its Cloudbreak antiviral conjugates (AVCs) for influenza SAN DIEGO --(BUSINESS WIRE)--Mar.
03/07/19
Cidara Therapeutics Announces Rezafungin Presentations at the 2019 European Society for Blood and Marrow Transplantation Meeting
SAN DIEGO --(BUSINESS WIRE)--Mar. 7, 2019-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that three rezafungin abstracts have been accepted for presentation at the 45 th Annual European Society for
02/28/19
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results
SAN DIEGO , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2018 and provided an update on its
02/05/19
Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting
SAN DIEGO --(BUSINESS WIRE)--Feb. 5, 2019-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from studies of its lead antifungal rezafungin will be presented at the 2019 Transplantation and
12/03/18
Cidara Therapeutics Appoints James Levine as CFO and Jessica Oien as General Counsel and Secretary
SAN DIEGO --(BUSINESS WIRE)--Dec. 3, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointments of James (Jamie) Levine as chief financial officer and Jessica Oien , J.D., as general counsel
11/27/18
Cidara Therapeutics to Present New Data at ASH 2018 Highlighting Potential of Rezafungin to Prevent Invasive Fungal Infections in Bone Marrow Transplant Patients
SAN DIEGO --(BUSINESS WIRE)--Nov. 27, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting the potential of rezafungin to prevent invasive fungal
11/12/18
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year
Employee feedback places Cidara among top 15 small companies in the area SAN DIEGO --(BUSINESS WIRE)--Nov. 12, 2018-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace
11/08/18
Cidara Provides Corporate Update and Reports Third Quarter 2018 Financial Results
SAN DIEGO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2018 and provided an update on its corporate
10/24/18
Cidara Therapeutics to Present New Data Highlighting Its Cloudbreak Immunotherapy Platform at the 2018 World Antimicrobial Resistance Congress
SAN DIEGO --(BUSINESS WIRE)--Oct. 24, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting its Cloudbreak™ immunotherapy discovery platform and new
10/15/18
Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference
SAN DIEGO --(BUSINESS WIRE)--Oct. 15, 2018-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in